06:05 PM EDT, 10/03/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Thursday the US Food and Drug Administration has approved Opdivo for the treatment of adult patients with resectable non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent Opdivo as adjuvant treatment after surgery.

The approval is based on results from the CheckMate-77T trial, the company said, adding that Opdivo is the only approved PD-1 inhibitor for resectable NSCLC in both a neoadjuvant-only regimen and as part of a perioperative treatment regimen.

Price: 54.35, Change: +0.15, Percent Change: +0.28